{"name":"Tedec-Meiji Farma, S.A.","slug":"tedec-meiji-farma-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CS+SG","genericName":"CS+SG","slug":"cs-sg","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"CS+SG","genericName":"CS+SG","slug":"cs-sg","phase":"phase_3","mechanism":"CS+SG is a combination therapy that likely combines two active pharmaceutical components to enhance therapeutic efficacy through complementary mechanisms.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPX2gta1pGeTR3NGowNkJCOWd1SjlFWDBZN3FXZndtRFNzUzg3dkNxbDZSNFdRclg5TW04YzJOdkpmM3NUSjdyaTdwRkRBdVlSdzE5UnNxRlB3NnJTdUt4OXZEcUd1a1JvZWkzSHcwOWFXNi1HRWJXdHVOT3RnYmZ0MkdmNG5SaENDSkllTjQ2VEZudktWMlUyOW1jQnROdkc1STF0cURSU1dKcDFN?oc=5","date":"2019-07-17","type":"pipeline","source":"PR Newswire","summary":"OrthogenRx CEO Awarded 2019 Entrepreneur of the Year - PR Newswire","headline":"OrthogenRx CEO Awarded 2019 Entrepreneur of the Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPbl9BajFQU2xYbVlHT0tLQTlhdnU5ZzJaVXdoeEh1a1Y2Tm43ZEtoYlMtMmdRTXcycmZyVnB4S3dWOUNsNGNaUGFRLVFlc2JWbVhieDc2UWRzTmlrX1V5eVh2R3NoTW94dmFROVhPLWlxeUFDT3NnN3RvcGJIWDZwcVhtc1A5NVZ3?oc=5","date":"2019-01-22","type":"pipeline","source":"BioSpace","summary":"OrthogenRx Launches TriVisc® (sodium hyaluronate) in the US - BioSpace","headline":"OrthogenRx Launches TriVisc® (sodium hyaluronate) in the US","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}